BioPharma Dive July 16, 2024
Jonathan Gardner

The startup will use the financing to advance a pair of cardiovascular medicines and potentially add new therapies to its portfolio.

Dive Brief:

  • Biotechnology startup Cardurion Pharmaceuticals on Tuesday raised a $260 million Series B round that will help it build its portfolio of heart disease drugs.
  • Cardurion will use the funds to advance a pair of medicines into mid- and late-stage testing, run studies in newer indications and potentially acquire other assets for cardiovascular diseases. The round comes two months after the startup detailed data from a Phase 2 trial in heart failure.
  • Ascenta Capital led the financing, which involved NEA, GV, Bain Capital Life Sciences and a handful of other investors. Bain has already invested heavily...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Ono pays $280M to license Ionis rare disease drug

Share This Article